Shares of Orthofix Medical Inc. (NASDAQ:OFIX) experienced a significant drop of 5.8% during trading on Tuesday, January 16, 2024, following the release of the company’s quarterly earnings report, which fell short of expectations. The stock traded as low as $12.39 before closing at $12.80. This marked a notable decline from the previous closing price of $13.59. Approximately 185,213 shares changed hands, a decrease of 17% from the average daily trading volume of 223,713 shares.
In its latest earnings report, Orthofix Medical recorded a loss of ($0.06) earnings per share (EPS), significantly missing the consensus estimate of $0.44 by ($0.50). The company reported a revenue of $219.91 million, which slightly exceeded analyst expectations of $218.72 million. Despite this revenue beat, Orthofix faced challenges, reflected in its negative net margin of 14.56% and a negative return on equity of 25.59%.
Market Reactions and Analyst Insights
Following the earnings report, several analysts provided their assessments of the company’s prospects. Barrington Research maintained an “outperform” rating and set a price target of $18.00. Meanwhile, TD Cowen initiated coverage with a “hold” rating and a price target of $14.00. In contrast, Stifel Nicolaus began coverage with a “buy” rating and a price objective of $22.00, while Weiss Ratings reiterated a “sell (d-)” rating. Overall, market sentiment reflects a mixed outlook, with four analysts recommending a buy, two suggesting a hold, and one advising a sell. According to MarketBeat, the stock currently holds a consensus rating of “hold” with an average target price of $20.00.
Insider Trading Activity
In a notable development, CEO Massimo Calafiore sold 9,797 shares of the company’s stock on January 12, 2024, at an average price of $15.21, totaling approximately $149,012.37. Post-sale, Calafiore retains 217,237 shares valued at around $3.3 million, indicating a 4.32% reduction in his ownership. CFO Julie Andrews also sold 4,873 shares on January 16, 2024, at an average price of $14.38, amounting to about $70,073.74. This transaction reduced her holdings by 7.75%, leaving her with 58,039 shares valued at approximately $834,600. Over the past quarter, insiders have sold a total of 24,270 shares worth $370,958, with insiders now holding 1.30% of the company’s stock.
Institutional Investor Activity
Institutional investors have shown varied interest in Orthofix Medical. Recently, CWM LLC increased its stake by 99.0% in the third quarter, now holding 1,920 shares valued at $28,000 after acquiring an additional 955 shares. The State of Alaska Department of Revenue also entered the fray, acquiring a new stake worth approximately $30,000. Other institutional investments include Kestra Advisory Services LLC, which purchased a new position valued at around $56,000, and Mackenzie Financial Corp, acquiring a new stake worth about $148,000. Overall, institutional investors and hedge funds own approximately 89.76% of Orthofix Medical’s stock.
Orthofix Medical operates as a global medical device company, specializing in innovative orthopedic and spinal solutions. Its business is divided into two primary segments: spine and orthopedics. The company offers a variety of titanium implants, biologics, and portable bone growth stimulation devices aimed at supporting spinal fusion and minimally invasive procedures. The orthopedic segment includes products for fracture fixation and sports medicine, catering to complex bone reconstruction and healing.
As the company navigates this challenging quarter, stakeholders will closely monitor its strategic moves and market responses in the coming months.
